Skip to main content
EW
NYSE Life Sciences

Edwards Beats on 11.2% Growth, Raises Full-Year Sales and EPS Guidance

Tom Rudovsky · Reported by BusinessWire
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$99.99
Mkt Cap
$57.277B
52W Low
$74.66
52W High
$100.253
52W Position info
34% above low
Off High info
at 52W high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

EW sits 34% above its 52-week low of $74.66 on elevated volume (2.2× avg).

Summary

Q3 sales rose 10.5% to $1.72 billion, or 11.2% in constant currency, and adjusted EPS of $0.80 grew 19% year over year — management called the growth above expectations. TMTT did the heavy lifting at $207 million, up 44%, while TAVR grew 8.0% to $1.24 billion with stable global pricing and modest U.S. share gains. The company raised full-year 2026 sales growth guidance to about 11.5% from 10%-11%, lifted TAVR growth to 9.0%-9.5% from 8%-9%, and nudged TMTT to $780-$790 million from $760-$780 million; adjusted EPS guidance moves to $2.97-$3.05. GAAP results were hit by a $220.2 million impairment of an acquired IPR&D asset and fixed assets, which is why GAAP EPS was only $0.53, and net income came in at $307.5 million. This lands after a strong clinical stretch — the PROGRESS trial win and CLASP II TR data on Nov 2, plus the October PASCAL tricuspid approval — and offsets the October FDA high-risk recall warning on Commander M delivery systems. Q4 guidance of $1.67-$1.75 billion in sales and $0.61-$0.69 adjusted EPS implies the growth is expected to hold through year-end.

At the time of this announcement, EW was trading at $99.99 on NYSE in the Life Sciences sector, with a market capitalization of approximately $57.3B. The 52-week trading range was $74.66 to $100.25. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

EW - Latest Insights

EW
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $103.00
Real-time Price: $103.95 info
Change: +$0.950 (+0.92%) info
Market Cap: $59.731B info
EW
Nov 04, 2026, 4:21 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $104.54
Real-time Price: $103.95 info
Change: -$0.590 (-0.56%) info
Market Cap: $59.731B info
EW
Nov 02, 2026, 1:25 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $90.76
Real-time Price: $103.95 info
Change: +$13.19 (+15%) info
Market Cap: $59.731B info
EW
Nov 02, 2026, 12:40 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $95.17
Real-time Price: $103.95 info
Change: +$8.78 (+9%) info
Market Cap: $59.731B info
EW
Oct 21, 2026, 10:07 AM EDT
Source: dpa-AFX
Importance Score:
8
Price at Filing: $87.12
Real-time Price: $103.95 info
Change: +$16.83 (+19%) info
Market Cap: $59.731B info